Cell Reports volume 5, issue 2, P302-313 2013 DOI: 10.1016/j.celrep.2013.09.009 View full text
Sathish Kumar Mungamuri, William Murk, Luca Grumolato, Emily Bernstein, Stuart A. Aaronson

Abstract: SUMMARY ErbB2 gene amplification occurs in 20–25% of breast cancers, and its therapeutic targeting has markedly improved survival of such patients in the adjuvant setting. However resistance to these therapies can develop. Because epigenetic mechanisms can importantly influence oncogene expression and be druggable as well, we investigated histone modifications that influence ErbB2 overexpression, independent of gene amplification. We demonstrate here that ErbB2 overexpressing breast carcinomas acquire the H3K…

expand abstract